Nine Lives: Alcon’s Pataday Brochure Draws Yet Another FDA Letter
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s most recent advertising letter to Alcon about its marketing practices makes the ninth such letter sent to the ophthalmology-focused firm in roughly 10 years; this time, the Office of Prescription Drug Promotion says the Novartis unit has omitted material facts and overstated efficacy and superiority in a brochure for Pataday.
You may also be interested in...
‘Tis The Season… For An FDA Enforcement Letter To Alcon
The eighth enforcement letter from FDA in a decade cites the company for unjustified claims about its seasonal allergic rhinitis drug, Patanase.
Rebate Card For Alcon’s Pataday Is More Than Meets The Eye, FDA Says
Promotion is not a reminder ad since the ophthalmic’s indication is depicted graphically, a notice of violation letter contends. Citation about advertising and promotional infractions is the second in about a year for Alcon Research.
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.